Early and exudative age-related macular degeneration is associated with increased plasma levels of soluble TNF receptor II

Acta Ophthalmologica

Volumn 93, Issue 3, 2015, Pages 242-247

  Faber, Carsten ^a,b   Jehs, Tina ^a   Juel, Helene Bæk ^a   Singh, Amardeep ^a,c   Falk, Mads Krüger ^a,b,c   Sørensen, Torben Lykke ^a,c   Nissen, Mogens Holst ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

age related macular degeneration; cytokine; inflammation; plasma; sTNFRII

Indexed keywords

COMPLEMENT FACTOR H; GAMMA INTERFERON; INTERLEUKIN 15; INTERLEUKIN 18; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER; COMPLEMENT FACTOR H, HUMAN; IL15 PROTEIN, HUMAN; INTERLEUKIN 18 PROTEIN, HUMAN;

ADULT; AGE; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CASE CONTROL STUDY; CELL ACTIVITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DENMARK; DISEASE ASSOCIATION; GENOTYPE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING HABIT; T LYMPHOCYTE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; EXUDATE; FEMALE; GENETICS; GENOTYPING TECHNIQUE; MALE; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; BIOMARKERS; CASE-CONTROL STUDIES; COMPLEMENT FACTOR H; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXUDATES AND TRANSUDATES; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INTERLEUKIN-15; INTERLEUKIN-18; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; WET MACULAR DEGENERATION;

EID: 84927671061     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12581     Document Type: Article

References (51)

1. Ambati J, Atkinson JP, &, Gelfand BD, (2013): Immunology of age-related macular degeneration. Nat Rev Immunol 13: 438-451.
2. Anderson DH, Radeke MJ, Gallo NB, et al. (2009): The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 29: 95-112.
3. Ardeljan D, &, Chan CC, (2013): Aging is not a disease: distinguishing age-related macular degeneration from aging. Prog Retin Eye Res 37: 68-89.
4. Aukrust P, Froland SS, Liabakk NB, Muller F, Nordoy I, Haug C, &, Espevik T, (1994): Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84: 2136-2143.
5. Barbara JA, Van ostade X, &, Lopez A, (1996): Tumour necrosis factor-alpha (TNF-alpha): the good, the bad and potentially very effective. Immunol Cell Biol 74: 434-443.
6. Cao X, Shen D, Patel MM, Tuo J, Johnson TM, Olsen TW, &, Chan CC, (2011): Macrophage polarization in the maculae of age-related macular degeneration: a pilot study. Pathol Int 61: 528-535.
7. Cherepanoff S, McMenamin P, Gillies MC, Kettle E, &, Sarks SH, (2010): Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol 94: 918-925.
8. Correia MP, Costa AV, Uhrberg M, Cardoso EM, &, Arosa FA, (2011): IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology 216: 604-612.
9. la Cour M, Kiilgaard JF, &, Nissen MH, (2002): Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging 19: 101-133.
10. Cousins SW, Espinosa-Heidmann DG, &, Csaky KG, (2004): Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol 122: 1013-1018.
11. Doyle SL, Campbell M, Ozaki E, et al. (2012): NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by Drusen components. Nat Med 18: 791-798.
12. Erke MG, Bertelsen G, Peto T, Sjolie AK, Lindekleiv H, &, Njolstad I, (2014): Cardiovascular risk factors associated with age-related macular degeneration: the Tromso study. Acta Ophthalmol [Epub ahead of print].
13. Faber C, Singh A, Kruger FM, Juel HB, Sorensen TL, &, Nissen MH, (2013): Age-related macular degeneration is associated with increased proportion of CD56 T cells in peripheral blood. Ophthalmology 120: 2310-2316.
14. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, &, Dayer JM, (1992): Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology 76: 20-23.
15. Haas P, Aggermann T, Nagl M, Steindl-Kuscher K, Krugluger W, &, Binder S, (2011): Implication of CD21, CD35, and CD55 in the pathogenesis of age-related macular degeneration. Am J Ophthalmol 152: 396-399.
16. van Hagen PM, Baarsma GS, van Bilsen CE, et al. (2014): A noncontrolled trial of anti-TNF-alpha chimeric monoclonal antibody (infliximab, remicade) in exudative age-related macular degeneration. Acta Ophthalmol [Epub ahead of print].
17. Holtkamp GM, Kijlstra A, Peek R, &, De Vos AF, (2001): Retinal pigment epithelium-immune system interactions: cytokine production and cytokine-induced changes. Prog Retin Eye Res 20: 29-48.
18. Hong T, Tan AG, Mitchell P, &, Wang JJ, (2011): A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv Ophthalmol 56: 184-194.
19. Juel HB, Faber C, Udsen MS, Folkersen L, &, Nissen MH, (2012): Chemokine expression in retinal pigment epithelial ARPE-19 cells in response to coculture with activated T cells. Invest Ophthalmol Vis Sci 53: 8472-8480.
20. Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, &, Kaarniranta K, (2012): Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-implications for age-related macular degeneration (AMD). Immunol Lett 147: 29-33.
21. Klein R, Klein BEK, Knudtson MD, Wong TY, Shankar A, &, Tsai MY, (2005): Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol 140: 35.
22. Klein R, Knudtson MD, Klein BE, et al. (2008): Inflammation, complement factor H, and age-related macular degeneration: the multi-ethnic study of atherosclerosis. Ophthalmology 115: 1742-1749.
23. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, &, Saaddine JB, (2011): Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 129: 75-80.
24. Klein R, Myers CE, Cruickshanks KJ, et al. (2014): Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver dam eye study. JAMA Ophthalmol 132: 446-455.
25. Kotter I, Koch S, Vonthein R, Ruckwaldt U, Amberger M, Gunaydin I, Zierhut M, &, Stubiger N, (2005): Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 23: S20-S26.
26. Kubicka-Trzaska A, Wilanska J, Romanowska-Dixon B, &, Sanak M, (2014): Circulating anti-retinal antibodies in response to anti-angiogenic therapy in exudative age-related macular degeneration. Acta Ophthalmol [Epub ahead of print].
27. Liu B, Faia L, Hu M, &, Nussenblatt RB, (2010): Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells. Mol Vis 16: 184-193.
28. Liu MM, Chan CC, &, Tuo J, (2012): Genetic mechanisms and age-related macular degeneration: common variants, rare variants, copy number variations, epigenetics, and mitochondrial genetics. Hum Genomics 6: 13.
29. Luo C, Chen M, &, Xu H, (2011): Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid. Mol Vis 17: 1588-1597.
30. Machalinska A, Dziedziejko V, Mozolewska-Piotrowska K, Karczewicz D, Wiszniewska B, &, Machalinski B, (2009): Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 42: 54-59.
31. Mahmoud RAK, El-Gendi HI, &, Ahmed HH, (2005): Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem 38: 134-141.
32. Miller JW, (2013): Age-related macular degeneration revisited-piecing the puzzle: the LXIX Edward Jackson Memorial Lecture. Am J Ophthalmol 155: 1-35.
33. Mo FM, Proia AD, Johnson WH, Cyr D, &, Lashkari K, (2010): Interferon gamma-inducible protein-10 (IP-10) and eotaxin as biomarkers in age-related macular degeneration. Invest Ophthalmol Vis Sci 51: 4226-4236.
34. Owczarek D, Cibor D, Glowacki MK, Ciesla A, &, Mach P, (2012): TNF-alpha and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis. Pol Arch Med Wewn 122: 616-623.
35. Papadakis KA, Prehn JL, Landers C, Han Q, Luo X, Cha SC, Wei P, &, Targan SR, (2004): TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 172: 7002-7007.
36. Penfold PL, Killingsworth MC, &, Sarks SH, (1985): Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch Clin Exp Ophthalmol 223: 69-76.
37. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, &, Seddon JM, (2009): Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 50: 5818-5827.
38. Rutenfranz I, &, Kirchner H, (1988): Pharmacokinetics of recombinant murine interferon-gamma in mice. J Interferon Res 8: 573-580.
39. van der Schaft TL, Mooy CM, de Bruijn WC, &, de Jong PT, (1993): Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study. Br J Ophthalmol 77: 657-661.
40. Scholl HPN, Issa PC, Walier M, et al. (2008): Systemic complement activation in age-related macular degeneration. PLoS ONE 3: e2593.
41. Seddon JM, Gensler G, Milton RC, Klein ML, &, Rifai N, (2004): Association between C-reactive protein and age-related macular degeneration. JAMA 291: 704-710.
42. Seddon JM, George S, Rosner B, &, Rifai N, (2005): Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 123: 774-782.
43. Seddon JM, Sharma S, &, Adelman RA, (2006): Evaluation of the clinical age-related maculopathy staging system. Ophthalmology 113: 260-266.
44. Singh A, Faber C, Falk M, Nissen MH, Hviid TV, &, Sorensen TL, (2012): Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration. Am J Ophthalmol 154: 193-199.
45. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR, &, Chong NV, (2007): Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol 125: 515-519.
46. Smailhodzic D, Klaver CCW, Klevering BJ, et al. (2012): Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology 119: 339-346.
47. Tarallo V, Hirano Y, Gelfand BD, et al. (2012): DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell 149: 847-859.
48. Terasaki H, Kase S, Shirasawa M, et al. (2013): TNF-alpha decreases VEGF secretion in highly polarized RPE cells but increases it in non-polarized RPE cells related to crosstalk between JNK and NF-kappaB pathways. PLoS ONE 8: e69994.
49. Van Hauwermeiren F, Vandenbroucke RE, &, Libert C, (2011): Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1. Cytokine Growth Factor Rev 22: 311-319.
50. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, &, Lowry SF, (1992): Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci 89: 4845-4849.
51. van de Wetering D, de Paus RA, van Dissel JT, &, van de Vosse E, (2009): IL-23 modulates CD56+/CD3- NK cell and CD56+/CD3+ NK-like T cell function differentially from IL-12. Int Immunol 21: 145-153.